Data Exclusivity – The Impact of Article 39.3 in India: A Practical Perspective Data Exclusivity – The Impact of Article 39.3 in India: A Practical Perspective – I-MAK

Data Exclusivity – The Impact of Article 39.3 in India: A Practical Perspective

18 Jul 2006
View Resource

Using examples of medicines that are already on the market, and some which do not yet have marketing approval in India, we attempt to demonstrate how the current proposal of a three-year data exclusivity period would impact access to these medicines.

Partner with us now to build
a more just and equitable
medicine system for all.